Compare AbCellera Biologics Inc (ABCL) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Mega Cap Growth ETF — how do they compare? AbCellera Biologics Inc trades at $9.21 (market cap $2.99B), while Vanguard Mega Cap Growth ETF trades at $90.47. Which is the better fit depends on your goals.
| ABCL | MGK | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $9.76 | $92.06 |
52-Week Low | $2.78 | $70.70 |
Enterprise Value | $2.58B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
